Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Leber Congenital Amaurosis

Eye & Vision

Leber Congenital Amaurosis (LCA) Clinical Trials

Also called LCA, Leber congenital blindness, retinal dystrophy

Leber congenital amaurosis (LCA) encompasses a group of rare autosomal recessive or less commonly autosomal dominant inherited retinal dystrophies characterized by severe vision impairment or blindness present at birth or in early infancy. The condition results from mutations in genes encoding proteins critical for photoreceptor development and function, with over 25 different genetic subtypes identified to date.

In plain words, Leber congenital amaurosis is a group of inherited eye conditions that cause severe vision loss from birth or early infancy. Gene changes harm the light-sensing cells at the back of the eye, and sight can worsen over time.

Get an email when new Leber Congenital Amaurosis trials open or the FDA decides. Get alerts

Leber Congenital Amaurosis

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 3 studies with no phase, like observational studies.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines1

Luxturna

Leber Congenital Amaurosis has 1 FDA-approved medicine, 5 open or active clinical trials (4 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Leber Congenital Amaurosis

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Leber Congenital Amaurosis

These mutations lead to progressive degeneration of retinal photoreceptor cells, particularly cone and rod photoreceptors, resulting in severely compromised vision from the earliest months of life. Patients typically present with severe vision loss, nystagmus (involuntary eye movements), and abnormal pupillary responses. Over time, progressive retinal degeneration leads to complete vision loss in most cases.

Keep reading about Leber Congenital Amaurosis

Clinical examination reveals pale, waxy optic discs and attenuated retinal vessels. Electroretinography shows nonrecordable or severely reduced responses in both photopic and scotopic conditions, a hallmark diagnostic finding. Fundus imaging demonstrates progressive retinal atrophy with variable presentation depending on the genetic subtype.

This genetic heterogeneity has critical implications for treatment, as recent gene therapies are subtype-specific and can only benefit patients carrying mutations in targeted genes. Early genetic testing is therefore essential for prognostication and accessing emerging therapies.

What are the symptoms of Leber Congenital Amaurosis?

These are common symptoms of Leber Congenital Amaurosis, and how strong they are varies from person to person.

  • Severe vision loss or blindness from birth or early infancy
  • Nystagmus (involuntary eye movements)
  • Photophobia (light sensitivity)
  • Hyperopia and astigmatism
  • Pupillary abnormalities
  • Retinal degeneration on imaging

Who gets Leber Congenital Amaurosis?

Leber congenital amaurosis presents from birth or within the first few weeks to months of life. The condition affects males and females equally across all ethnic groups, though certain genetic subtypes and mutations show higher prevalence in specific populations. For example, LCA subtypes caused by mutations in genes like CEP290 and RPE65 are found worldwide, while some rarer subtypes show regional clustering.

Inheritance follows autosomal recessive patterns for the majority of cases, meaning both parents must carry mutations; less commonly autosomal dominant inheritance occurs.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Leber Congenital Amaurosis?

There is currently 1 FDA-approved medication for Leber Congenital Amaurosis.

voretigene neparvovec-rzyl
Spark Therapeutics (Roche); distributed in the US by Genentech
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

How to get help paying for Leber Congenital Amaurosis treatment

Charity funds and drugmaker programs for Leber Congenital Amaurosis, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds

No charity fund for this condition is open right now. Funds reopen when they receive new donations; the foundations let you sign up to be told when one opens.

Status as each foundation showed it on November 16, 2026.
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Every program and fund for Leber Congenital Amaurosis, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Leber Congenital Amaurosis

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Leber Congenital Amaurosis resources

Reputable organizations and medical references for learning more about Leber Congenital Amaurosis, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Leber Congenital Amaurosis

Use this Leber Congenital Amaurosis clinical trial finder to see the 4 studies recruiting patients and 1 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 3 test a treatment and 2 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

5 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 1/2Recently updatedNCT07681778

Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD)

Intervention: OPGx-RDH12

Sponsor: Opus Genetics, Inc

This study is an early-stage clinical trial (Phase 1b/2a) testing a gene therapy called OPGx-RDH12 for people with Leber Congenital Amaurosis (LCA) caused by mutations in the RDH12 gene, a rare genetic eye disease that leads to severe vision loss. The treatment is delivered as a ...

Ages 18 Years+4 locations
Expected to start Oct 2026Updated 2 weeks agoEst. Dec 2032 (~6y 1m)
RecruitingPatient registry covering many conditionsRecently updatedNCT01793168

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

Sponsor: Sanford Health

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute...

Ages not specified1 location
Started Jul 2010Updated 3 weeks agoEst. Dec 2100 (~74y 2m)
RecruitingTreatment trialPhase 3Recently updatedNCT06891443

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

Intervention: sepofarsen, Placebo IVT

Sponsor: Laboratoires Thea · Sepul Bio

The purpose of this double-masked, randomized, placebo-controlled, paired-eye study is to evaluate the efficacy, safety and tolerability of Sepofarsen in subjects with Leber Congenital Amaurosis (LCA) due to the c.2991+1655A>G (p.Cys998X) mutation in the CEP290.

Ages 6 Years+
Started Jun 2025Updated 4 weeks agoEst. Nov 2027 (~1 year)
RecruitingPatient registry covering many conditionsNo updates in a whileNCT02435940

Inherited Retinal Degenerative Disease Registry

Sponsor: Foundation Fighting Blindness

The My Retina Tracker® Registry is sponsored by the Foundation Fighting Blindness and is for people affected by one of the rare inherited retinal degenerative diseases studied by the Foundation. org. Affected individuals who register are guided to create a profile that captures t...

Ages not specified1 location
Started Jun 2014Updated 6 months agoEst. Jun 2037 (~10y 7m)
Not yet recruitingTreatment trialHasn't posted an update in over a yearNCT06024057

An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy(LX101) in Patients With LCA

Intervention: LX101

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

To evaluate the scaling clinical trail of AAV2-RPE65 gene therapy agent (LX101) in patients with congenital amaurosis (LCA).

Ages 18 Years+
Expected to start Sep 2023Updated 3 years agoEst. Sep 2028 (~1y 10m)
Find Leber Congenital Amaurosis trials near you, ranked by distance →
Active trial locations10 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+2 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 1
Phase 3
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Leber Congenital Amaurosis trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Leber Congenital Amaurosis foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Leber Congenital Amaurosis patient communities

Facebook groups, Reddit communities and YouTube channels where Leber Congenital Amaurosis patients, caregivers and advocacy groups talk.

Companies developing Leber Congenital Amaurosis treatments

Drugmakers that list Leber Congenital Amaurosis in their rare disease portfolio, 1 in all.

Questions people ask about Leber Congenital Amaurosis